Sign in to view content

A Phase 1, Multicenter, Prospective, Open-Label, Dose Escalation Study of EYP-1901, a Tyrosine Kinase Inhibitor (TKI), in Subjects With Wet AMD

Vrinda S. Hershberger, MD, PhD

Video
Published 2021

Related

Episode 23: CANTREAT Study. Ranibizumab Monthly vs Treat-and-Extend for wAMD with Dr. Peter Kertes
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019
Wet AMD 5 Symposium
Annual Meeting Talks
2020
Episode 131: Journal Club on Follow-up for AMD and PDR Patients, Phase II and III Clinical Trials, Ophthalmology Chairs in the U.S. with Dr. M. Ali Khan
Jayanth Sridhar, MD
Member Podcasts
2018

Category: AMD-Neovascular

See more